155 BOVET RD., SUITE 303, SAN MATEO, CA
Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Sagimet Biosciences Inc. Enters Underwriting Agreement for $164.5M Offering
Investor Presentation
Annual Report to Security Holders
Material disclosure
Targeting Metabolic Dysfunction with Novel Therapies to Treat M ASH, Acne & Cancer
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Submission Upload
Correspondence